C promoter binding factor 1 (CBF1) (alias RBPJ) is a critical transcription factor involved in Notch signaling. The activation of Notch signaling through CBF1 maintains the angiostatic state of endothelial cells suppressing angiogenesis, that is, the formation of new blood vessels. Vascular endothelial growth factor (VEGF) induces angiogenesis by promoting the proteasomal degradation of CBF1, in addition to endothelial cell proliferation. To date, angiogenic inhibitors targeting VEGF have been successfully used in clinics for cancer and age-related macular degeneration. Most antiangiogenic drugs, however, only target VEGF or VEGF receptors. In this study, to expand the repertoire of antiangiogenic therapeutics, we developed 15 single-stranded deoxyribonucleic acid (ssDNA) aptamers capable of binding to CBF1 with high affinity (Kd; 10–300 nM). To this end, systematic evolution of ligands by the exponential enrichment (SELEX) method was applied. One of the CBF1-binding ssDNA aptamers, Apt-3, inhibited angiogenesis through the activation of Notch signaling in vitro. We found that Apt-3 directly interacted with the LAG1 domain of CBF1. We suggest that the Apt-3 ssDNA aptamer may contribute to the development of a novel angiogenic inhibitor, which does not target VEGF.
Get full access to this article
View all access options for this article.
References
1.
ZhouJ and RossiJ. (2017). Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov, 16:181–202.
2.
ZhangY, LaiBS and Juhas.M (2019). Recent advances in aptamer discovery and applications. Molecules, 24:941.
3.
EllingtonAD and SzostakJW. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346:818–822.
4.
TuerkC and GoldL. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249:505–510.
5.
NgEW, ShimaDT, CaliasP, CunninghamETJr., GuyerDR and AdamisAP. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov, 5:123–132.
6.
PotenteM, GerhardtH and CarmelietP. (2011). Basic and therapeutic aspects of angiogenesis. Cell, 146:873–887.
7.
SakaueT, MaekawaM, NakayamaH and HigashiyamaS. (2017). Prospect of divergent roles for the CUL3 system in vascular endothelial cell function and angiogenesis. J Biochem, 162:237–245.
8.
ShawberCJ and KitajewskiJ. (2004). Notch function in the vasculature: insights from zebrafish, mouse and man. Bioessays, 26:225–234.
9.
AlvaJA and Iruela-ArispeML. (2004). Notch signaling in vascular morphogenesis. Curr Opin Hematol, 11:278–283.
10.
LiJL and HarrisAL. (2005). Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell, 8:1–3.
11.
OhnukiH, InoueH, TakemoriN, NakayamaH, SakaueT, FukudaS, MiwaD, NishiwakiE, HatanoM, et al. (2012). BAZF, a novel component of cullin3-based E3 ligase complex, mediates VEGFR and Notch cross-signaling in angiogenesis. Blood, 119:2688–2698.
12.
CarmelietP and JainRK. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature, 473:298–307.
13.
DouGR, WangYC, HuXB, HouLH, WangCM, XuJF, WangYS, LiangYM, YaoLB, et al. (2008). RBP-J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice. FASEB J, 22:1606–1617.
14.
ClarkeJM and HurwitzHI. (2013). Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol, 4:253–263.
15.
BergersG and HanahanD. (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer, 8:592–603.
16.
LupoG, CaporarelloN, OlivieriM, CristaldiM, MottaC, BramantiV, AvolaR, SalmeriM, NicolettiF, et al. (2016). Anti-angiogenic therapy in cancer: downsides and new pivots for precision medicine. Front Pharmacol, 7:519.
17.
EskensFA and VerweijJ. (2006). The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer, 42:3127–3139.
18.
van WijngaardenP, CosterDJ and WilliamsKA. (2005). Inhibitors of ocular neovascularization: promises and potential problems. JAMA, 293:1509–1513.
19.
TanigawaK, MaekawaM, KiyoiT, NakayamaJ, KitazawaR, KitazawaS, SembaK, TaguchiT, AkitaS, et al. (2019). SNX9 determines the surface levels of integrin beta1 in vascular endothelial cells: implication in poor prognosis of human colorectal cancers overexpressing SNX9. J Cell Physiol, 234:17280–17294.
20.
UematsuA, KidoK, TakahashiH, TakahashiC, YanagiharaY, SaekiN, YoshidaS, MaekawaM, HondaM, et al. (2019). The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD. J Biol Chem, 294:14135–14148.
21.
LatoSM, BolesAR and EllingtonAD. (1995). In vitro selection of RNA lectins: using combinatorial chemistry to interpret ribozyme evolution. Chem Biol, 2:291–303.
22.
MukaiK, KonnoH, AkibaT, UemuraT, WaguriS, KobayashiT, BarberGN, AraiH and Taguchi.T (2016). Activation of STING requires palmitoylation at the Golgi. Nat Commun, 7:11932.
23.
El KebirD, JózsefL, PanW, WangL and FilepJG. (2009). Bacterial DNA activates endothelial cells and promotes neutrophil adherence through TLR9 signaling. J Immunol, 182:4386–4394.
24.
WatanabeR, MaekawaM, HiedaM, TaguchiT, MiuraN, KikugawaT, SaikaT and HigashiyamaS. (2020). SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex. Mol Biol Cell, 31:478–490.
25.
MaekawaM, TanigawaK, SakaueT, HiyoshiH, KubotaE, JohT, WatanabeY, TaguchiT and HigashiyamaS. (2017). Cullin-3 and its adaptor protein ANKFY1 determine the surface level of integrin beta1 in endothelial cells. Biol Open, 6:1707–1719.
26.
StoltenburgR, ReinemannC and StrehlitzB. (2007). SELEX—a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng, 24:381–403.
27.
Mathews DH. (2006). RNA secondary structure analysis using RNAstructure. Curr Protoc Bioinformatics Chapter 12: Unit 12.6.
28.
ArnaoutovaI and KleinmanHK. (2010). In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc, 5:628–635.
29.
IshikawaH, MaZ and BarberGN. (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature, 461:788–792.
30.
AryanZ and RezaeiN. (2015). Toll-like receptors as targets for allergen immunotherapy. Curr Opin Allergy Clin Immunol, 15:568–574.
31.
LanG, LinZ, ZhangJ, LiuL, ZhangJ, ZhengL and LuoQ. (2019). Notch pathway is involved in the suppression of colorectal cancer by embryonic stem cell microenvironment. Onco Targets Ther, 12:2869–2878.
32.
El-GebaliS, MistryJ, BatemanA, EddySR, LucianiA, PotterSC, QureshiM, RichardsonLJ, SalazarGA, et al. (2019). The Pfam protein families database in 2019. Nucleic Acids Res, 47:D427–D432.
33.
SawasakiT, OgasawaraT, MorishitaR and EndoY. (2002). A cell-free protein synthesis system for high-throughput proteomics. Proc Natl Acad Sci U S A, 99:14652–14657.
34.
TakahashiH, UematsuA, YamanakaS, ImamuraM, NakajimaT, DoiK, YasuokaS, TakahashiC, TakedaH, et al. (2016). Establishment of a wheat cell-free synthesized protein array containing 250 human and mouse E3 ubiquitin ligases to identify novel interaction between E3 ligases and substrate proteins. PLoS One, 11:e0156718.
35.
NamY, AsterJC and BlacklowSC. (2002). Notch signaling as a therapeutic target. Curr Opin Chem Biol, 6:501–509.
36.
HurtadoC, SafarovaA, SmithM, ChungR, BruyneelAAN, Gomez-GalenoJ, OswaldF, LarsonCJ, CashmanJR, et al. (2019). Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ. Sci Rep, 9:10811.
37.
TorellaR, LiJ, KinradeE, Cerda-MoyaG, ContrerasAN, FoyR, StojnicR, GlenRC, KovallRA, et al. (2014). A combination of computational and experimental approaches identifies DNA sequence constraints associated with target site binding specificity of the transcription factor CSL. Nucleic Acids Res, 42:10550–10563.
38.
YuanZ, VanderWielenBD, GiaimoBD, PanL, CollinsCE, TurkiewiczA, HeinK, OswaldF, BorggrefeT, et al. (2019). Structural and functional studies of the RBPJ-SHARP complex reveal a conserved corepressor binding site. Cell Rep, 26:845–854.e846.
39.
FriedmannDR, WilsonJJ and KovallRA. (2008). RAM-induced allostery facilitates assembly of a notch pathway active transcription complex. J Biol Chem, 283:14781–14791.
40.
TabajaN, YuanZ, OswaldF and KovallRA. (2017). Structure-function analysis of RBP-J-interacting and tubulin-associated (RITA) reveals regions critical for repression of Notch target genes. J Biol Chem, 292:10549–10563.
41.
VanderWielenBD, YuanZ, FriedmannDR and KovallRA. (2011). Transcriptional repression in the Notch pathway: thermodynamic characterization of CSL-MINT (Msx2-interacting nuclear target protein) complexes. J Biol Chem, 286:14892–14902.
42.
NamY, SlizP, SongL, AsterJC and BlacklowSC. (2006). Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell, 124:973–983.
43.
KovallRA and HendricksonWA. (2004). Crystal structure of the nuclear effector of Notch signaling, CSL, bound to DNA. EMBO J, 23:3441–3451.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
